Myovant Stock Insiders

MYOV -  USA Stock  

USD 20.28  0.22  1.07%

Myovant Sciences employes about 407 people. The company is managed by 19 executives with total tenure of roughly 63 years, averaging almost 3.0 years of service per executive having 21.42 employees per reported executive. Recap of Myovant Sciences management performance can provide insight into the venture performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Myovant Sciences future performance.
Additionally, see Stocks Correlation.

Search Insiders 

  Myrtle Potter  Chairman
Chairman of the Board
  Frank Karbe  President
Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.
  Jeffrey Nornhold  President
Senior Vice President Pharmaceutical Operations & Development

Myovant Sciences Management Team Effectiveness

Myovant Sciences has return on total asset (ROA) of (35.36) % which means that it has lost $35.36 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 20.67 %, meaning that it created $20.67 on every $100 dollars invested by stockholders. Myovant Sciences management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Equity is likely to climb to 1.09 in 2021, whereas Return on Average Assets are likely to drop (0.63)  in 2021. Myovant Sciences Total Assets are fairly stable at the moment as compared to the past year. Myovant Sciences reported Total Assets of 725.03 Million in 2020. Current Assets is likely to climb to about 760.3 M in 2021, whereas Return on Average Assets are likely to drop (0.63)  in 2021.

Myovant Sciences Quarterly Total Assets

725.03 MillionShare
Issuance Purchase of Equity Shares is likely to climb to about 6.9 M in 2021, whereas Weighted Average Shares is likely to drop slightly above 88.1 M in 2021.

Myovant Sciences Workforce Comparison

Myovant Sciences is considered to be number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 1,811. Myovant Sciences totals roughly 407 in number of employees claiming about 22% of stocks in Biotechnology industry.

Myovant Sciences Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Myovant Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Myovant Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Myovant Sciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Myovant Sciences Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. Myovant Sciences Price Series Summation is a cross summation of Myovant Sciences price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Myovant Sciences Notable Stakeholders

A Myovant Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Myovant Sciences often face trade-offs trying to please all of them. Myovant Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Myovant Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Myrtle Potter - Chairman of the BoardProfile
Frank Karbe - Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.Profile
Jeffrey Nornhold - Senior Vice President Pharmaceutical Operations & DevelopmentProfile
Keith Manchester - DirectorProfile
Mark Altmeyer - Independent DirectorProfile
Frank Torti - DirectorProfile
Vivek Ramaswamy - DirectorProfile
Wayne DeVeydt - Independent DirectorProfile
Kathleen Sebelius - Lead Independent DirectorProfile
Mark Guinan - Independent DirectorProfile
Terrie Curran - Independent DirectorProfile
Lynn Seely - Principal Executive Officer, DirectorProfile
Juan Ferreira - Chief Commercial Officer - Myovant Sciences, IncProfile
Marianne Romeo - Head, Global Transactions & Risk ManagementProfile
Kim Sablich - Chief Commercial OfficerProfile
Matthew Lang - General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.Profile
Adele Gulfo - Director, Interim Chief Commercial OfficerProfile
David Marek - Principal Executive Officer, DirectorProfile
Hiroshi Nomura - DirectorProfile

About Myovant Sciences Management Performance

The success or failure of an entity such as Myovant Sciences often depends on how effective the management is. Myovant Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Myovant management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Myovant management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Return on Average Assets(0.58) (0.63) 
Return on Average Equity 1.06  1.09 
Return on Invested Capital(1.38) (1.49) 
Return on Sales(3.71) (4.00) 
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womens health and endocrine diseases. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Myovant Sciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 407 people.
The data published in Myovant Sciences' official financial statements usually reflect Myovant Sciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Myovant Sciences. For example, before you start analyzing numbers published by Myovant accountants, it's critical to develop an understanding of what Myovant Sciences' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Myovant Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Myovant Sciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Myovant Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Myovant Sciences. Please utilize our Beneish M Score to check the likelihood of Myovant Sciences' management to manipulate its earnings.

Myovant Sciences Workforce Analysis

Traditionally, organizations such as Myovant Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Myovant Sciences within its industry.

Myovant Sciences Manpower Efficiency

Return on Myovant Sciences Manpower

Revenue Per Employee145.7 K
Revenue Per Executive3.1 M
Net Loss Per Employee626.9 K
Net Loss Per Executive13.4 M
Working Capital Per Employee302.3 K
Working Capital Per Executive6.5 M
Additionally, see Stocks Correlation. Note that the Myovant Sciences information on this page should be used as a complementary analysis to other Myovant Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for Myovant Stock analysis

When running Myovant Sciences price analysis, check to measure Myovant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Myovant Sciences is operating at the current time. Most of Myovant Sciences' value examination focuses on studying past and present price action to predict the probability of Myovant Sciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Myovant Sciences' price. Additionally, you may evaluate how the addition of Myovant Sciences to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
The market value of Myovant Sciences is measured differently than its book value, which is the value of Myovant that is recorded on the company's balance sheet. Investors also form their own opinion of Myovant Sciences' value that differs from its market value or its book value, called intrinsic value, which is Myovant Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myovant Sciences' market value can be influenced by many factors that don't directly affect Myovant Sciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myovant Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Myovant Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myovant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.